Yoshihiro Morimoto

1.2k total citations
68 papers, 870 citations indexed

About

Yoshihiro Morimoto is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Yoshihiro Morimoto has authored 68 papers receiving a total of 870 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 21 papers in Molecular Biology and 17 papers in Surgery. Recurrent topics in Yoshihiro Morimoto's work include Pancreatic and Hepatic Oncology Research (7 papers), RNA modifications and cancer (7 papers) and Immune Response and Inflammation (7 papers). Yoshihiro Morimoto is often cited by papers focused on Pancreatic and Hepatic Oncology Research (7 papers), RNA modifications and cancer (7 papers) and Immune Response and Inflammation (7 papers). Yoshihiro Morimoto collaborates with scholars based in Japan, United States and Germany. Yoshihiro Morimoto's co-authors include Satoshi Shimizu, Mitsuhiko Noda, Kazuyuki Inoue, Daisuke Ito, Kouichi Inukai, Akira Shimada, M. Yanagisawa, Yuji Akiyama, Hiromi Iwagaki and Nobuyuki Tanaka and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Diabetes Care.

In The Last Decade

Yoshihiro Morimoto

61 papers receiving 855 citations

Peers

Countries citing papers authored by Yoshihiro Morimoto

Since Specialization

Citations

This map shows the geographic impact of Yoshihiro Morimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshihiro Morimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshihiro Morimoto more than expected).

Fields of papers citing papers by Yoshihiro Morimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshihiro Morimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshihiro Morimoto. The network helps show where Yoshihiro Morimoto may publish in the future.

Co-authorship network of co-authors of Yoshihiro Morimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshihiro Morimoto. A scholar is included among the top collaborators of Yoshihiro Morimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshihiro Morimoto. Yoshihiro Morimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of adjuvant chemotherapy after curative hepatectomy for patients with colorectal cancer liver metastases: a single-center retrospective study 2024 ·World Journal of Surgical Oncology ·Akira Inoue, Yujiro Nishizawa, Masahiro Hashimoto, (unknown), Yoshihiro Morimoto, Akira Tomokuni, Masaaki Motoori, (unknown)	0
2	IDENTIFICATION OF MUC1-C AS A TARGET FOR SUPPRESSING PROGRESSION OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS 2024 ·Cancer Research Communications ·(unknown), Naoki Haratake, Atrayee Bhattacharya, Weipu Mao, (unknown), Keyi Wang, (unknown), Hiroki Ozawa, Keisuke Shigeta, Atsushi Fushimi, Nami Yamashita, Yoshihiro Morimoto, Mototsugu Shimokawa, Shin Saito, Ann Marie Egloff, Ravindra Uppaluri, Mark D. Long, Donald Küfe	4
3	[A Case of Curative Resection for Primary Small Bowel Cancer and Lymph Node Metastasis Incidentally found during Surgery for Colorectal Cancer]. 2024 ·PubMed ·Genki Okumura, Akira Inoue, Yoshinori Kagawa, Yujiro Nishizawa, Masahiro Hashimoto, (unknown), Yoshihiro Morimoto, (unknown), (unknown), (unknown), Masashi Hirota, Yasuhiro Miyazaki, Akira Tomokuni, Masaaki Motoori, Kazumasa Fujitani	0
4	MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression 2024 ·Oncogene ·Atrayee Bhattacharya, (unknown), (unknown), Chi Ngai Chan, Atsushi Fushimi, Nami Yamashita, (unknown), Naoki Haratake, Hiroki Ozawa, (unknown), Keisuke Shigeta, Yoshihiro Morimoto, Masaaki Miyo, Donald Küfe	9
5	MUC1-C intersects chronic inflammation with epigenetic reprogramming by regulating the set1a compass complex in cancer progression 2023 ·Communications Biology ·Atrayee Bhattacharya, Atsushi Fushimi, Keyi Wang, Nami Yamashita, Yoshihiro Morimoto, Satoshi Ishikawa, (unknown), Tao Liu, Song Liu, Mark D. Long, Donald Küfe	13
6	Abstract B089: MUC1-C is a common driver of acquired osimertinb resistance in NSCLC 2023 ·Molecular Cancer Therapeutics ·Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, (unknown), Atrayee Bhattacharya, Keyi Wang, (unknown), Hideko Isozaki, Aaron N. Hata, Donald Küfe	2
7	MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells 2023 ·Journal for ImmunoTherapy of Cancer ·Yoshihiro Morimoto, Nami Yamashita, (unknown), (unknown), (unknown), Naoki Haratake, Satoshi Ishikawa, Atrayee Bhattacharya, Atsushi Fushimi, Rehan Ahmad, Hidekazu Takahashi, Olga Dashevsky, Constantine S. Mitsiades, Donald Küfe	16
8	MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC 2023 ·Journal of Thoracic Oncology ·Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, (unknown), Atrayee Bhattacharya, Keyi Wang, (unknown), Hideko Isozaki, Mototsugu Shimokawa, Chie Kikutake, Mikita Suyama, (unknown), Kazuki Takada, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Tetsuya Mitsudomi, Aaron N. Hata, Donald Küfe	24
9	MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells 2023 ·iScience ·Nami Yamashita, Henry Withers, Yoshihiro Morimoto, Atrayee Bhattacharya, Naoki Haratake, (unknown), Atsushi Fushimi, (unknown), Aaron R. Thorner, (unknown), Spencer R. Rosario, Mark D. Long, Donald Küfe	7
10	MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer 2022 ·Molecular Cancer Research ·Nami Yamashita, Yoshihiro Morimoto, Atsushi Fushimi, Rehan Ahmad, Atrayee Bhattacharya, (unknown), Naoki Haratake, (unknown), Satoshi Ishikawa, Masaaki Yamamoto, Tsuyoshi Hata, Sayuri Akiyoshi, Qiang Hu, Tao Liu, Henry Withers, Song Liu, Geoffrey I. Shapiro, Tomoharu Yoshizumi, Mark D. Long, Donald Küfe	25
11	Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment 2022 ·Oncogene ·Yoshihiro Morimoto, Atsushi Fushimi, Nami Yamashita, Masayuki Hagiwara, Atrayee Bhattacharya, Jingwei Cheng, (unknown), Rehan Ahmad, (unknown), Lei Huang, Tsuyoshi Hata, Hidekazu Takahashi, Masaaki Yamamoto, Yozo Suzuki, James A. DeCaprio, Donald Küfe	16
12	Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer 2022 ·Molecular Cancer Research ·Atsushi Fushimi, Yoshihiro Morimoto, Satoshi Ishikawa, Nami Yamashita, Atrayee Bhattacharya, (unknown), Hasan Rajabi, Caining Jin, Masayuki Hagiwara, Yota Yasumizu, (unknown), (unknown), Kwok‐Kin Wong, Henry Withers, Song Liu, Mark D. Long, Donald Küfe	12
13	A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer 2022 ·Annals of Gastroenterological Surgery ·Chu Matsuda, Toshihiro Kudo, Yoshihiro Morimoto, Yoshinori Kagawa, Mitsuyoshi Tei, (unknown), Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Ichiro Takemasa, Taroh Satoh, Tsunekazu Mizushima, Kohei Murata, Yuichiro� Doki, Hidetoshi Eguchi	4
14	Improved In Vivo Delivery of Small RNA Based on the Calcium Phosphate Method 2021 ·Journal of Personalized Medicine ·Xin Wu, Yuhki Yokoyama, Hidekazu Takahashi, (unknown), Hiroyuki Yamamoto, Jiaqi Wang, Yoshihiro Morimoto, Kazumasa Minami, Tsuyoshi Hata, Awad Shamma, Akira Inoue, Masahisa Ohtsuka, Satoshi Shibata, Shogo Kobayashi, Shuji Akai, Hirofumi Yamamoto	8
15	Single-site laparoscopic right hemicolectomy for acute cecal volvulus: a case report 2016 ·Surgical Case Reports ·Yoshinori Kagawa, Takeshi Kato, Atsushi Naito, Yoshihiro Morimoto, Yasufumi Sato, (unknown), Tomo Ishida, (unknown), Kohei Murakami, (unknown), (unknown), Yoshiaki Ohmura, Atsushi Takeno, Chiyomi Egawa, Yutaka Takeda, Shigeyuki Tamura	4
16	Activated T Cells and Soluble Molecules in the Portal Venous Blood of Patients with Cholestatic and Hepatitis C Virus-Positive Liver Cirrhosis. Possible Promotion of Fas/FasL-Mediated Apoptosis in the Bile-Duct Cells and Hepatocyte Injury 2003 ·Journal of International Medical Research ·(unknown), Yoshihiro Morimoto, Takahito Yagi, (unknown), (unknown), Hiroshi Sadamori, Masaru Inagaki, Naoto Urushihara, Hiromi Iwagaki, Nobuyuki Tanaka	6
17	Donor Dendritic Cells and Recipient Kupffer Cells in the Induction of Donor-Specific Immune Hyporesponsiveness 2001 ·Journal of International Medical Research ·Kei Nakagawa, T Matsuno, Hiromi Iwagaki, Yoshihiro Morimoto, T Fujiwara, Hiroshi Sadamori, Masaru Inagaki, Naoto Urushihara, Takahito Yagi, Nobuyuki Tanaka	7
18	Changes in natural killer cell activity in normal pregnant and postpartum women: increases in the first trimester and postpartum period and decrease in late pregnancy 1991 ·Journal of Reproductive Immunology ·Yoh Hidaka, Nobuyuki Amino, Yoshinori Iwatani, T Kaneda, Nobuaki Mitsuda, Yoshihiro Morimoto, Osamu Tanizawa, K Miyai	39
19	Paragonimus infection in weasels produced in Miyazaki Prefecture, Japan. 1980 ·(unknown), Shigehisa Habe, Tohru Murakami, (unknown), S. Tateyama, Yoshihiro Morimoto	1
20	1977 ·JOURNAL OF THE JAPAN WELDING SOCIETY ·Toshihiko Okada, Yoshihiro Morimoto, (unknown), (unknown), Ryoichi Takayama	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact